Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alnylam Pharmaceuticals is conducting a Phase 1 study titled ‘A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma.’ The study aims to evaluate the safety, tolerability, and antitumor activity of ALN-BCAT, both as a standalone treatment and in combination with pembrolizumab, in patients with advanced liver cancer. The significance of this study lies in its potential to offer new therapeutic options for a challenging cancer type.
The interventions being tested include ALN-BCAT, administered via intravenous infusion, and pembrolizumab, also delivered intravenously. ALN-BCAT is being assessed both as a monotherapy and in combination with pembrolizumab to determine the most effective and safe dosage for future studies.
The study follows a non-randomized, parallel intervention model with no masking, focusing primarily on treatment. This design allows for a clear assessment of the drug’s effects in different therapeutic settings.
The study began on December 30, 2024, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on July 15, 2025, indicating ongoing progress in the trial.
From a market perspective, this study could significantly impact Alnylam Pharmaceuticals’ stock performance, as successful results might boost investor confidence and position the company as a leader in innovative cancer treatments. The competitive landscape includes other pharmaceutical companies exploring similar therapies, which could influence market dynamics.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.